VIP Dosage: Doses Studied, Units and Chart
What doses of VIP have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 6 studies
- with a stated dose, listed below
- Frequency
- Varies by study
- as used in studies
- Half-life
- Not found
- No published half-life found (PubMed search, 11 Oct 2026)
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| target 600, 1200 and 1800 pmol/kg on days 1 to 3 | daily 12-hour infusion · intravenous · 3 days | Human RCTn = 461 | The Lancet. Respiratory medicine 2023, PMID 37348524 |
| not stated in abstract | not stated · intravenous · 3 days | Human RCTn = 196 | Critical care medicine 2022, PMID 36044317 |
| 1, 3 and 6 pmol/kg/min | 15 minutes per dose · intravenous infusion | Human controlled trial | Thorax 1986, PMID 3787552 |
| aviptadil with phentolamine | self-administered · intracavernosal injection | Human observationaln = 308 | The journal of sexual medicine 2025, PMID 40192471 |
| 100-microg single dose | single dose · inhaled | Human uncontrolled trialn = 20 | The European respiratory journal 2008, PMID 18978135 |
| 400 pmol/kg/hr | constant · intravenous infusion · 100 minutes | Human uncontrolled trialn = 6 | The American journal of cardiology 1987, PMID 3687785 |
Before anyone considers it
- VIP is not FDA approved for any use.
- Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
Intravenous aviptadil in COVID-19 respiratory failure
In the TESICO trial in COVID-19 respiratory failure, intravenous aviptadil (the drug form of VIP) was given as a 12-hour infusion on 3 days, targeting 600, 1200 and 1800 pmol/kg on days 1, 2 and 3.[3]
Drugs@FDA lists no VIP product, so no US label gives an amount.[17]
Inhaled and injected amounts in other uses
In 20 patients with pulmonary hypertension, a single inhaled 100-microg dose of aviptadil caused a small, temporary pulmonary vasodilation.[7]
For refractory erectile dysfunction, aviptadil was combined with phentolamine as an intracavernosal injection. The abstract states no per-injection amount.[6]
Common questions
Is VIP FDA approved?
No. VIP is not FDA approved for any use.
What is the VIP peptide dosing?
It depends on the route. In pulmonary hypertension, 20 patients inhaled a single 100-microg dose of aviptadil.[7]
Is there a VIP peptide protocol or cycle?
None is sourced. Drugs@FDA lists no VIP product, and the studies here used intravenous, inhaled and intracavernosal routes for unrelated conditions.[17]
More on VIP
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.The Lancet. Respiratory medicine · 2023PMID 37348524Accessed 2 Oct 2026
- 4The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.Critical care medicine · 2022PMID 36044317Accessed 2 Oct 2026
- 5Effect of infused vasoactive intestinal peptide on airway function in normal subjects.Thorax · 1986PMID 3787552Accessed 2 Oct 2026
- 6Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction.The journal of sexual medicine · 2025PMID 40192471Accessed 2 Oct 2026
- 7Inhalation of vasoactive intestinal peptide in pulmonary hypertension.The European respiratory journal · 2008PMID 18978135Accessed 2 Oct 2026
- 8Cardiovascular effects of vasoactive intestinal peptide in healthy subjects.The American journal of cardiology · 1987PMID 3687785Accessed 2 Oct 2026
- 9PubMed search: aviptadil[tiab] (30 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: aviptadil[tiab] AND (randomized[tiab] OR "clinical trial"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: (aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab] OR "vasoactive intestinal polypeptide"[tiab]) AND (randomized[tiab] OR trial[tiab] OR patients[tiab]) (1509 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: (aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (70 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: "vasoactive intestinal peptide"[tiab] AND (CIRS[tiab] OR "inflammatory response syndrome"[tiab] OR mycotoxin*[tiab] OR "water-damaged"[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: "vasoactive intestinal peptide"[tiab] AND ("clinical trial"[pt] OR randomized[tiab]) AND (inhal*[tiab] OR intranasal[tiab] OR sarcoid*[tiab] OR "pulmonary hypertension"[tiab] OR ARDS[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: aviptadil[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 16PubMed search: (aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR tolerab*[tiab] OR toxicity[tiab]) AND (humans[mh]) (94 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 17Drugs@FDA (openFDA) search: active ingredient "vasoactive intestinal peptide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.